en · de · es · fr · pt
sermorelin-notes.peptides9002.com › Guide › Chemical Identity Of Bremelanotide — Deep Dive

Chemical Identity Of Bremelanotide — Deep Dive

By Editorial Desk · published 2025-08-23 · last reviewed 2025-09-12 · Guide

MC4 receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.

Chemical Identity of Bremelanotide

Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

Peptide Handling and Storage Practice

Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.

Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.

Pt-141 at a glance

PropertyValueNotes
Chemical classCyclic peptideMelanocortin receptor agonist family
Molecular weightApproximately 1025 DaFree base form
AppearanceWhite to off-white powderLyophilized product
SolubilitySoluble in waterAlso dissolves in polar organic solvents
Storage temperature-20 degrees CelsiusDry and protected from light

Receptor Mechanism and Trial Evidence

Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.

Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.

Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.

Related pages on this site

Receptor Pharmacology and Study Measures

Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.

Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.

Receptor Mechanism And Pharmacokinetics

Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.

The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.

Supporting material

== History == The concept of microneedles was first derived from the use of large hypodermic needles in the 1970s, but it only became prominent in the 1990s as microfabrication manufacturing technology developed. Later, the concept of MNs finally came into experimentation in 1994 when Orentreich discovered the insertion of tri-beveled needles to the skin could possibly stimulates the release of fibrous strand. The investigation on MNs' potential to improve transdermal drug delivery gradually raised public awareness of MNs. Since then, there has been massive research conducted on MNs, contributing to the development of different materials, types, and fabrication methods of MNs. Application and adverse events are explored. In the 2000s, clinical trials on MNs' use in drug delivery began. Microneedles were first mentioned in a 1998 paper by the research group headed by Mark Prausnitz at the Georgia Institute of Technology that demonstrated that microneedles could penetrate the uppermost layer (stratum corneum) of the human skin and were therefore suitable for the transdermal delivery of therapeutic agents. Subsequent research into microneedle drug delivery has explored the medical and cosmetic applications of this technology through its design. This early paper sought to explore the possibility of using microneedles in the future for vaccination. Since then researchers have studied microneedle delivery of insulin, vaccines, anti-inflammatories, and other pharmaceuticals. In dermatology, microneedles are used for scarring treatment with skin rollers.

== Other animals == In dogs, OI is an autosomal recessive condition, meaning that dogs with two copies of the allele will be affected. Many breed organizations and veterinarians offer OI tests to tell if a dog is a carrier of OI. To prevent OI, dogs who are heterozygous for OI should not be bred. Naturally occurring mutations causing OI have been found in Golden Retrievers, Dachshunds, and Beagles. OI has also been identified in zebrafish and mice. Although dogs, mice, fish, and humans are not genetically identical, some of these animal models have been officially recognized to represent the varying types of OI in humans. For example, homozygous oim/oim mice experience spontaneous bone fractures, small body size, and kyphosis, making them a model of OI type III. Meanwhile, heterozygous oim/+ mice appear normal but have bones which are quite a bit weaker than wild mice, making them a model for OI type I. As in human OI, the location on the gene which is mutated affects the severity of resulting disease—the G859C Col1a1 mouse is a model for OI type II as affected mice all die in the perinatal period. Animal testing on identified animal models may lead to human therapies for OI.

The primary cell wall derives its notable tensile strength from cellulose molecules, or long-chains of glucose residues stabilized by hydrogen bonding. Cellulose chains are observed to align in overlapping parallel arrays, with the similar polarity forming a cellulose microfibril. In plants, these cellulose microfibrils arrange themselves into layers, formally known as lamellae, and are stabilized in the cell wall by surface, long cross-linking glycan molecules. Glycan molecules increase the complexity of the potential networks plant-based cellulose can configure itself into. Coextensive in the primary cell wall to both cellulose microfibrils and complementary glycan networks, is pectin which is a polysaccharide that contains many negatively charged galacturonic acid units. Additionally, cellulose microfibrils also contribute to the shape of the plant via controlled-cell expansion. The stereoscopic arrangement of microfibrils in the cell wall create systems of turgor pressure which ultimately leads to cellular growth and expansion. Cellulose microfibrils are unique matrix macromolecules, in that they are assembled by cellulose synthase enzymes located on the extracellular surface of the plasma membrane. It is believed that the plant can "anticipate their future morphology by controlling the orientation of microfibrils" by a mechanism where cellulose microfibrils are arranged atop a cortical array of microtubules.

== Further reading == Extracellular matrix: review of its roles in acute and chronic wounds Usage of Extracellular Matrix from pigs to regrow human extremities Sound Medicine - Heart Tissue Regeneration – July 19 interview discussing ECM and its uses in cardiac tissue repair (requires MP3 playback).

=== Liver disease === Liver fibrosis and cirrhosis are associated with the deposition of collagen IV in the liver. Serum collagen IV concentrations correlate with hepatic tissue levels of collagen IV in subjects with alcoholic liver disease and hepatitis C and fall following successful therapy.

Sources: en.wikipedia.org

Supporting material

== Formation == The creation process of type I collagen begins with the production and the combination of two separate subunits, called the pro-alpha1(I) and pro-alpha2(I) chains. These pro-alpha chains are encoded by the COL1A1 and COL1A2 genes respectively and when combined produce type I pro-collagen. This transcriptional process takes place within the cell's endoplasmic reticulum and must undergo post-translational modifications in order to make the final type I collagen product. The procollagen complex is then modified by different enzyme proteinases which cleave N and C terminal pro-peptides that are present on either side of the molecule. This process occurs outside of the cellular membrane at which post processing, the molecules cross link and form a final type I collagen product.

Tendons are viscoelastic structures, which means they exhibit both elastic and viscous behaviour. When stretched, tendons exhibit typical "soft tissue" behavior. The force-extension, or stress-strain curve starts with a very low stiffness region, as the crimp structure straightens and the collagen fibres align suggesting negative Poisson's ratio in the fibres of the tendon. More recently, tests carried out in vivo (through MRI) and ex vivo (through mechanical testing of various cadaveric tendon tissue) have shown that healthy tendons are highly anisotropic and exhibit a negative Poisson's ratio (auxetic) in some planes when stretched up to 2% along their length, i.e. within their normal range of motion. After this 'toe' region, the structure becomes significantly stiffer, and has a linear stress-strain curve until it begins to fail. The mechanical properties of tendons vary widely, as they are matched to the functional requirements of the tendon. The energy storing tendons tend to be more elastic, or less stiff, so they can more easily store energy, whilst the stiffer positional tendons tend to be a little more viscoelastic, and less elastic, so they can provide finer control of movement. A typical energy storing tendon will fail at around 12–15% strain, and a stress in the region of 100–150 MPa, although some tendons are notably more extensible than this, for example the superficial digital flexor in the horse, which stretches in excess of 20% when galloping. Positional tendons can fail at strains as low as 6–8%, but can have moduli in the region of 700–1000 MPa.

== Decay and capture products == A 135Xe atom that does not capture a neutron undergoes beta decay to 135Cs, one of the 7 long-lived fission products, while a 135Xe that does capture a neutron becomes almost-stable 136Xe. The probability of capturing a neutron before decay varies with the neutron flux, which itself depends on the kind of reactor, fuel enrichment and power level; and the 135Cs / 136Xe ratio switches its predominant branch very near usual reactor conditions. Estimates of the proportion of 135Xe during steady-state reactor operation that captures a neutron include 90%, 39%–91% and "essentially all". For instance, in a (somewhat high) neutron flux of 1014 n·cm−2·s−1, the xenon cross section of σ = 2.65×10−18 cm2 (2.65×106 barn) would lead to a capture probability of 2.65×10−4 s−1, which corresponds to a half-life of about one hour. Compared to the 9.14 hour half-life of 135Xe, this nearly ten-to-one ratio means that under such conditions, essentially all 135Xe would capture a neutron before decay. But if the neutron flux is lowered to one-tenth of this value, like in CANDU reactors, the ratio would be 50-50, and half the 135Xe would decay to 135Cs before neutron capture. 136Xe from neutron capture ends up as part of the eventual stable fission xenon which also includes 134Xe, 132Xe, and 131Xe produced by fission and beta decay rather than neutron capture. Nuclei of 133Xe, 137Xe, and 135Xe that have not captured a neutron all beta decay to isotopes of caesium.

The support "was not directed by anyone within the Contra movement who had an association with the CIA," and the committee found "no evidence that the CIA or the Intelligence Community was aware of these individuals' support."

Sources: en.wikipedia.org

Notes from published material

In the brain, zinc is stored in specific synaptic vesicles by glutamatergic neurons and can modulate neuronal excitability. It plays a key role in synaptic plasticity and so in learning. Zinc homeostasis also plays a critical role in the functional regulation of the central nervous system. Dysregulation of zinc homeostasis in the central nervous system that results in excessive synaptic zinc concentrations is believed to induce neurotoxicity through mitochondrial oxidative stress (e.g., by disrupting certain enzymes involved in the electron transport chain, including complex I, complex III, and α-ketoglutarate dehydrogenase), the dysregulation of calcium homeostasis, glutamatergic neuronal excitotoxicity, and interference with intraneuronal signal transduction. L- and D-histidine facilitate brain zinc uptake. SLC30A3 is the primary zinc transporter involved in cerebral zinc homeostasis.

the Kurchatov Institute, Russia's leading research and development institution in nuclear energy, where the first nuclear reactor in Europe was built the Landau Institute for Theoretical Physics the Institute for Theoretical and Experimental Physics the Kapitza Institute for Physical Problems the Steklov Institute of Mathematics The city contains 452 libraries, including 168 for children. The Russian State Library, founded in 1862, is the national library of Russia. This library contains more than 275 kilometers (171 mi) of shelves and 42 million items—including more than 17 million books and serial volumes, 13 million journals, 350,000 music scores and sound records, and 150,000 maps—making it the country's largest library and one of the world's largest. Items in 247 languages other than Russian account for 29% of the library's collection. The State Public Historical Library, founded in 1863, is the largest library specialising in Russian history. Its collection contains four million items in 112 languages, mostly on Russian and world history, heraldry, numismatics, and the history of science. On the subject of primary and secondary education, journalist Clifford J. Levy of The New York Times newspaper wrote in 2011:

== Poisoning == The prognosis is good for paracetamol overdoses if treatment is initiated up to 8 hours after the drug has been taken. Most hospitals stock the antidote (acetylcysteine), which replenishes the liver's supply of glutathione, allowing the NAPQI to be metabolized safely. Without early administration of the antidote, fulminant liver failure follows, often in combination with kidney failure, and death generally occurs within several days.

=== Possible expansion into other Latin American nations === In August of 2026, while visiting Panama, Hegseth proclaimed that the United States has made a military agreement with Colombia, Guatemala and Honduras to combat criminal drug organizations. Hegseth added that like the attacks on boats that the U.S. had been conducting in the East Pacific and the Caribbean, the attacks on drug traffickers on land would be the same. In addition, Hegseth stated that the U.S. would continue to pursue military cooperation with Ecuador. However, Guatemala later publicly repudiated Hegseth's claims.

Specific glycosylation has been shown to occur after the formation of the heptpeptide aglycone. Three separate glycosyl transferases are required for the glycosylation of the teicoplanin aglycone. Tei10* catalyses the addition of GlcNAc to residue 4, followed by deacetylation by Tei2*. The acyl chain (produced by the action of Tei30* and Tei13*) is then added by Tei11*. Tei1 then adds a second GlcNAc to the β-hydroxyl group of residue 6, followed by mannosylation of residue 7 catalysed by Tei3*.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is PT-141?

It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.

How was the compound originally identified?

It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.

Which synonyms appear for PT-141?

Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.

How should a lyophilized peptide be stored?

Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.

Network